154 related articles for article (PubMed ID: 33625041)
21. Association between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol.
Mulindwa F; Kamal H; Castelnuovo B; Bollinger RC; Schwarz JM; Brussealers N
PLoS One; 2022; 17(3):e0264792. PubMed ID: 35235607
[TBL] [Abstract][Full Text] [Related]
22. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
[TBL] [Abstract][Full Text] [Related]
23. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes.
McCann K; Shah S; Hindley L; Hill A; Qavi A; Simmons B; Serenata C; Sokhela S; Venter WDF
AIDS; 2021 Aug; 35(10):1657-1665. PubMed ID: 33927086
[TBL] [Abstract][Full Text] [Related]
24. Choice of antiretroviral therapy has low impact on weight gain.
Drechsler H; Ayers C; Oboho I; Enwerem N; Hanna J; Clark C; Kitchell E; Jain M; Luque A; Bedimo R
AIDS; 2024 Jun; ():. PubMed ID: 38831733
[TBL] [Abstract][Full Text] [Related]
25. Antiretroviral therapy in older people with HIV.
Richterman A; Sax PE
Curr Opin HIV AIDS; 2020 Mar; 15(2):118-125. PubMed ID: 31990705
[TBL] [Abstract][Full Text] [Related]
26. Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
Acharya A; Tagny CT; Mbanya D; Fonsah JY; Nchindap E; Kenmogne L; Jihyun M; Njamnshi AK; Kanmogne GD
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106437
[No Abstract] [Full Text] [Related]
27. Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons.
Biały M; Czarnecki M; Inglot M
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140673
[TBL] [Abstract][Full Text] [Related]
28. The pathogenesis of obesity in people living with HIV.
Bailin SS; Koethe JR; Rebeiro PF
Curr Opin HIV AIDS; 2024 Jan; 19(1):6-13. PubMed ID: 37934696
[TBL] [Abstract][Full Text] [Related]
29. Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis.
Bai R; Lv S; Wu H; Dai L
BMC Infect Dis; 2022 Feb; 22(1):118. PubMed ID: 35114968
[TBL] [Abstract][Full Text] [Related]
30. Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV.
Sekiya R; Muramatsu T; Ichiki A; Chikasawa Y; Bingo M; Yotsumoto M; Hagiwara T; Amano K; Kinai E
J Infect Chemother; 2023 Feb; 29(2):171-178. PubMed ID: 37589078
[TBL] [Abstract][Full Text] [Related]
31. Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV.
Sørensen EW; Gelpi M; Knudsen AD; Benfield T; Mocroft A; Nielsen SD
J Acquir Immune Defic Syndr; 2021 Dec; 88(5):e36-e38. PubMed ID: 34520441
[No Abstract] [Full Text] [Related]
32. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Squires K; Kityo C; Hodder S; Johnson M; Voronin E; Hagins D; Avihingsanon A; Koenig E; Jiang S; White K; Cheng A; Szwarcberg J; Cao H
Lancet HIV; 2016 Sep; 3(9):e410-e420. PubMed ID: 27562742
[TBL] [Abstract][Full Text] [Related]
33. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
[TBL] [Abstract][Full Text] [Related]
34. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.
Elliot E; Chirwa M; Boffito M
Curr Opin Infect Dis; 2017 Feb; 30(1):58-73. PubMed ID: 27798496
[TBL] [Abstract][Full Text] [Related]
35. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
Sax PE; Erlandson KM; Lake JE; Mccomsey GA; Orkin C; Esser S; Brown TT; Rockstroh JK; Wei X; Carter CC; Zhong L; Brainard DM; Melbourne K; Das M; Stellbrink HJ; Post FA; Waters L; Koethe JR
Clin Infect Dis; 2020 Sep; 71(6):1379-1389. PubMed ID: 31606734
[TBL] [Abstract][Full Text] [Related]
36. Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis.
Mulindwa F; Kamal H; Castelnuovo B; Byonanebye DM; Schwarz JM; Bollinger R; Brusselaers N
BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36754450
[TBL] [Abstract][Full Text] [Related]
37. Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen.
Darnell J; Jain S; Sun X; Qin H; Reynolds T; Karris MY; Hill LA
Medicine (Baltimore); 2021 Aug; 100(34):e27047. PubMed ID: 34449491
[TBL] [Abstract][Full Text] [Related]
38. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Kauppinen KJ; Aho I; Sutinen J
AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
[TBL] [Abstract][Full Text] [Related]
39. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
